Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice

  title={Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice},
  author={Heather Lyons Narver},
  journal={Lab Animal},
Nalbuphine is an inexpensive, non-controlled, opioid analgesic that has been in clinical use for decades. A kappa opioid receptor agonist and mu opioid receptor antagonist, nalbuphine causes fewer adverse effects than other opioid analgesics. The author reviews the characteristics of nalbuphine, analyzes studies of nalbuphine in mice and explores the potential use of nalbuphine to treat pain in research mice. In analgesiometric studies in mice, nalbuphine ameliorates both somatic and visceral… 
Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.
It is suggested that nalbuphine is absorbed in and eliminated quickly from mice, making it a possible candidate for acute pain management.
A comprehensive review of partial opioid agonists for the treatment of chronic pain.
Oliceridine is the only current selective partial agonist that agonizes specific pathways to promote analgesic effects and discourage adverse effects, including the nonselective partial agonists, levorphanol and tramadol.
Comparative Study of Efficacy of Preoperative Nalbuphine Hydrochloride and Pentazocine Lactate on Hemodynamic Response to Tracheal Intubation and Postoperative Analgesia
Nalbuphine is potent mixed opioid analgesic which can be used for attenuation of pressor response of tracheal intubation and for perioperative analgesia with minimal side effects.
Analgesia in clinically relevant rodent models of sepsis
Different concepts of analgesia in rodent models of sepsis focusing on opioid agonists as well as non-opioid analgesics are described and advantages and pitfalls in study design and side-effects are discussed.
Nitric Oxide Stimulates Acute Pancreatitis Pain via Activating the NF-κB Signaling Pathway and Inhibiting the Kappa Opioid Receptor
The results suggest that iNOS/NO/NF-κB/KOR may be a key mechanism of pain in AP, providing a theoretical basis for the use of peripheral-restricted KOR agonists for pain treatment in AP.
Pain management after ambulatory surgery: a prospective, multicenter, randomized, double-blinded parallel controlled trial comparing nalbuphine and tramadol
Nalbuphine can provide effective and safe pain relief in patients after ambulatory surgery, relative to tramadol.
Analgesia and Humane Endpoints for Rodents in Sepsis Research.
Numerous regulatory bodies around the world require analgesics for rodents undergoing surgery to induce sepsis, and options for analgesics include NSAIDs, local analgesics, and opioids.
Ivasivka K
In our work we aimed to study the pathomorphological manifestations among the structural components of the laryngeal mucosa and cartilage in the early stages of the experimental opioid effect. This
Part I: Minimum Quality Threshold in Preclinical Sepsis Studies (MQTiPSS) for Study Design and Humane Modeling Endpoints.
It is recommended that therapeutic interventions should be initiated after the septic insult replicating clinical care and survival follow-up should reflect the clinical time course of the infectious agent used in the sepsis model.
The article describes the rationale and features of ursodeoxycholic acid application in a wide range of hepatobiliary and extrahepatic pathology and the prospects for UDCA use are determined.


Use of the mixed agonist–antagonist nalbuphine in opioid based analgesia
Using nalbuphine as the sole opioid analgesic can satisfactorily cover mild to moderate pain with a low incidence of the common opioid side effects, and with care can be used concurrently with the more commonly employed mu-opioid agonists, yielding good analgesia while simultaneously decreasing the incidence and severity of mu-agonist side effects.
Nalbuphine. A preliminary review of its pharmacological properties and therapeutic efficacy.
Nalbuphine appears to offer a useful alternative to morphine in patients with moderate to severe pain and appears to produce satisfactory anaesthesia when used as a component of a 'balanced' anaesthesia technique, although a relatively low 'ceiling' effect for reduction of anaesthetic requirements with nal Buphine may limit its usefulness.
Nalbuphine, a mixed kappa 1 and kappa 3 analgesic in mice.
It is suggested that nalbuphine elicits analgesia through a complex interaction of supraspinal kappa 3 and spinal kappa 1 mechanisms.
Comparison of Antinociceptive Effects Induced by Kappa Opioid Agonists in Male and Female Mice.
There were no sex-related differences in response to more selective kappa opioid agonists on antinociception in mice under these conditions, suggesting that butorphanol is a mixed mu/kappa opioid with low efficacy.
The Antinociceptive Effect of Nalbuphine and Its Long-Acting Esters in Rats
It is concluded that, on an equimolar basis, nalbuphine esters produce relatively longer durations of action than nal Buphine HCl.
The antinociceptive effect of a long-acting nalbuphine preparation in rabbits.
The aim of this study was to evaluate the antinociceptive effect and duration of action of an oily dosage form of nalbuphine base and to see whether its effect could last longer compared with nal Buphine HCl.
Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine
Of the four agonist-antagonists tested, butorphanol seems to be least liikely to produce cross-tolerance with morphine.
Antinociceptive effect of a novel long-acting nalbuphine preparation.
In vitro studies demonstrated that nalbuphine base in sesame oil had the slowest drug-releasing profile of the different preparations, and therefore produced a long-lasting antinociceptive effect.
A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain
We develop a mechanistic model for post-operative pain and apply it to describe the pharmacodynamic effects of the kappa-opioids nalbuphine and naloxone administered either alone or in combination in
Evaluation of the interaction between acemetacin and opioids on the hargreaves model of thermal hyperalgesia
Data suggest that low doses of the acemetacin-opioids combination can interact synergistically at systemic level and therefore this drugs association may represent a therapeutic advantage for the clinical treatment of inflammatory pain.